Cargando…
Germline mutations in Chinese ovarian cancer with or without breast cancer
BACKGROUND: Ovarian and breast cancers are known to have significant genetic components. Considering the differences in the mutation spectrum across ethnicity, it is important to identify hereditary breast and ovarian cancer (HBOC) genes mutation in Chinese for clinical management. METHODS: Two coho...
Autores principales: | Kwong, Ava, Ho, Cecilia Yuen Sze, Shin, Vivian Yvonne, Au, Chun Hang, Luk, Wing Pan, Fung, Ling Hiu, Chan, Tsun‐Leung, Chan, Karen Kar Loen, Ngan, Hextan Yuen Sheung, Ma, Edmond Shiu Kwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266594/ https://www.ncbi.nlm.nih.gov/pubmed/35608067 http://dx.doi.org/10.1002/mgg3.1940 |
Ejemplares similares
-
How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
por: Kwong, Ava, et al.
Publicado: (2022) -
Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021) -
Effect on Germline Mutation Rate in a High-Risk Chinese Breast Cancer Cohort after Compliance with The National Comprehensive Cancer Network (NCCN) 2023 v.1 Testing Criteria
por: Kwong, Ava, et al.
Publicado: (2023) -
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient
por: Kwong, Ava, et al.
Publicado: (2021) -
Tamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 ‐year clinical experience in a tertiary referral center
por: Chan, Karen Kar Loen, et al.
Publicado: (2020)